DPP-4 inhibition by Saxagilptin prevents inflammation and renal injury by targeting the Nirp3/ASC inflammasome

Project: Other project

StatusFinished
Effective start/end date12/13/139/30/14

Funding

  • Bristol-Myers Squibb Company: $28,070.24